Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NBTXBullishIndustry Newsnews

High materiality8/10

NBTX Shows Promising Phase 1 Melanoma Signals; Supports Further Trials

Oct 24, 2026, 7:11 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive ORR/DCR and a non-trivial OS metric in a PD-1–resistant setting can lift near-term equity sentiment; IL-1β signal adds a potential biomarker angle, though the data is early and lacks randomized confirmation.

AI summary

What happened, with direct paths to the underlying reporting

NBTX announced updated Phase 1 results from Study 1100 in anti-PD-1-resistant primary cutaneous melanoma. ORR reached 41.7% (10/24) with 4 complete responses and a 75% disease control rate; median overall survival was 17.8 months. An exploratory analysis noted a rise in IL-1β, suggesting potential immunologic reactivity, and investigators called for randomized trials in PD-1 naïve or refractory patients.

NBTX reports updated Phase 1 results in anti-PD-1-resistant melanoma.
ORR 41.7% (10/24); 4 complete responses; DCR 75% (18/24); median OS 17.8 months.
Exploratory IL-1β increase observed post-treatment; warrants randomized trials.
Data presented at 2026 ESMO Congress; potential PD-1 naïve/refractory melanoma trials.
Cross-listed on NASDAQ (NBTX) and Euronext (NANO); near-term price sensitivity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.